Implications and Applications of Molecular Diagnostics in Neuro-Oncology
The field of central nervous system (CNS) oncology is rapidly changing with advances in molecular diagnostics. The therapeutic implications are being realized …
The field of central nervous system (CNS) oncology is rapidly changing with advances in molecular diagnostics. The therapeutic implications are being realized …
Background Adoptive cell therapy, such as chimeric antigen receptor (CAR)-T cell therapy, has improved patient outcomes for hematological malignancies. Currently, four of the six FDA-approved…
Salvage treatment with nivolumab plus ipilimumab following progression on nivolumab alone led to significant treatment-free survival in advanced ccRCC.
A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
Immunogenomic information displays predictive capability in terms of immunotherapy resistance in metastatic uveal melanoma.
Frontline pembrolizumab plus trastuzumab/chemotherapy improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.
Treatment with EVT801 was well tolerated and led to a stable disease rate of 46% in patients with advanced ovarian cancer.
David Y.T. Chen, MD, has been recognized as a 2024 Castle Connolly Top Doctor and named to Castle Connolly’s Top AAPI Doctors list.
In his closing remarks, Yi-Bin Chen, MD, shares his aspirations for the future of graft versus host disease management, emphasizing the need for further clinical…